rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6
|
pubmed:dateCreated |
2005-6-13
|
pubmed:abstractText |
The majority of cyclosporine-treated transplant recipients develop hypertension. Endothelin-1 (ET-1) has been suggested to mediate cyclosporine-induced vasoconstriction when binding to ET-A receptors. We hypothesized that cyclosporine-treated lung transplant recipients have an increased basal vascular resistance and an augmented response to ET-A receptor blockade.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1053-2498
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
665-70
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15949725-Adult,
pubmed-meshheading:15949725-Antihypertensive Agents,
pubmed-meshheading:15949725-Cyclosporine,
pubmed-meshheading:15949725-Female,
pubmed-meshheading:15949725-Forearm,
pubmed-meshheading:15949725-Humans,
pubmed-meshheading:15949725-Immunosuppressive Agents,
pubmed-meshheading:15949725-Infusions, Intra-Arterial,
pubmed-meshheading:15949725-Lung Transplantation,
pubmed-meshheading:15949725-Male,
pubmed-meshheading:15949725-Middle Aged,
pubmed-meshheading:15949725-Nitric Oxide Synthase,
pubmed-meshheading:15949725-Peptides, Cyclic,
pubmed-meshheading:15949725-Receptor, Endothelin A,
pubmed-meshheading:15949725-Regional Blood Flow,
pubmed-meshheading:15949725-Vascular Resistance,
pubmed-meshheading:15949725-omega-N-Methylarginine
|
pubmed:year |
2005
|
pubmed:articleTitle |
Blunted vascular response to endothelin-a receptor blockade in cyclosporine-treated lung transplant recipients.
|
pubmed:affiliation |
Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|